404 related articles for article (PubMed ID: 25980483)
1. Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.
Kumari V; Ettinger U; Lee SE; Deuschl C; Anilkumar AP; Schmechtig A; Corr PJ; Ffytche DH; Williams SC
Psychopharmacology (Berl); 2015 Sep; 232(17):3135-47. PubMed ID: 25980483
[TBL] [Abstract][Full Text] [Related]
2. [Cognition, schizophrenia and the effect of antipsychotics].
Stip E
Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
[TBL] [Abstract][Full Text] [Related]
3. Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
Purdon SE; Woodward N; Lindborg SR; Stip E
Psychopharmacology (Berl); 2003 Sep; 169(3-4):390-7. PubMed ID: 12827347
[TBL] [Abstract][Full Text] [Related]
4. Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.
Wasserman JI; Barry RJ; Bradford L; Delva NJ; Beninger RJ
Psychopharmacology (Berl); 2012 Jul; 222(1):173-83. PubMed ID: 22237855
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
6. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
7. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.
Ritsner M; Gibel A; Perelroyzen G; Kurs R; Jabarin M; Ratner Y
J Clin Psychopharmacol; 2004 Dec; 24(6):582-91. PubMed ID: 15538118
[TBL] [Abstract][Full Text] [Related]
8. A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics.
Kumari V; Antonova E; Geyer MA; Ffytche D; Williams SC; Sharma T
Int J Neuropsychopharmacol; 2007 Aug; 10(4):463-77. PubMed ID: 16923324
[TBL] [Abstract][Full Text] [Related]
9. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Cuesta MJ; Peralta V; Zarzuela A
Schizophr Res; 2001 Mar; 48(1):17-28. PubMed ID: 11278151
[TBL] [Abstract][Full Text] [Related]
10. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
11. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
12. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
13. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
[TBL] [Abstract][Full Text] [Related]
14. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
15. Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications.
Jerrell JM; Ramirez PM
Hum Psychopharmacol; 2008 Oct; 23(7):595-604. PubMed ID: 18680213
[TBL] [Abstract][Full Text] [Related]
16. Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
Ren XS; Lee AF; Huang YH; Hamed A; Herz L; Miller DR; Kazis LE
J Clin Pharm Ther; 2004 Oct; 29(5):471-81. PubMed ID: 15482392
[TBL] [Abstract][Full Text] [Related]
17. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
[TBL] [Abstract][Full Text] [Related]
18. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
19. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration.
Ritchie CW; Harrigan S; Mastwyk M; Macfarlane S; Cheesman N; Ames D
Int J Geriatr Psychiatry; 2010 Apr; 25(4):411-8. PubMed ID: 19946860
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]